Bioniche Named Among Top Employers in Canada

Posted by Laura Swartz

October 28, 2010 at 10:40 AM

Today, Bioniche Life Sciences Inc. (BNC-TSX), a research-based, technology-driven Canadian biopharmaceutical company, announced that it was named among the Top 50 Best Small and Medium Employers in Canada. Ranked 14th, Bioniche believes that its employees, who are also shareholders, are among the Company’s greatest assets. The rankings were determined using employee opinion surveys, an assessment of organization practices, and perspectives from the leadership team. More than 160 companies across Canada registered to participate in the study, which was conducted by the Queen’s Centre for Business Venturing, the Queen’s University School of Business, and Aon Hewitt.

Read More

Topics: Newsworthy Events, Bioniche, biopharmaceuticals

New research available at

Posted by Laura Swartz

October 25, 2010 at 10:42 AM

This morning, we at Crystal Research published a new Executive Informational Overview (go here to find out more about what is in an EIO) on Radient Pharmaceuticals Corp. (RPC-NYSE Amex). Read a brief overview of Radient below or visit our website at to access the full 64-page report at no charge.

Read More

Topics: New Research

Promising Clinical Events from Neuralstem and Peregrine

Posted by Laura Swartz

October 19, 2010 at 10:44 AM

Neuralstem, Inc. (CUR-NYSE Amex) announced on Monday of this week that it would begin enrolling the next group of patients into its ongoing Phase I ALS clinical trial. This trial seeks to demonstrate the safety of surgically injecting stem cells into the spinal cords of patients who are diagnosed with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease. To date, six non-ambulatory individuals have received stem cell injections in the lumbar spinal cord, and the trial’s Safety Monitoring Board has unanimously approved enrolling the next group of patients. The trial’s next patients will be ambulatory, which represent earlier stages of the disease than have been tested thus far. Ultimately, 18 ALS patients are expected to be enrolled in the Phase I trial, which is underway at Emory University in Atlanta, Georgia.

Read More

Topics: Newsworthy Events, Neuralstem

Corporate Update from TapImmune and Positive Phase II Data from ACT Biotech

Posted by Laura Swartz

October 15, 2010 at 10:46 AM

TapImmune Inc. (TPIV-OTC.BB), a developer of immunotherapeutics for cancer and infectious disease, yesterday provided investors with a corporate update of the Company’s progress during 2010. This year, TapImmune has announced important strategic collaborations with Aeras Global TB Vaccine Foundation and the Mayo Clinic. As well, the Company expects to start clinical trials in early 2011 of its immunotherapy for HER-2/neu-positive breast cancer patients. In September 2010, TapImmune strengthened its technical and strategic team through the appointments of new individuals, including Dr. Martin Cheever, a scientist at the Fred Hutchinson Cancer Research Center and the University of Washington. Dr. Cheever was recently awarded a $14 million grant from the National Institutes of Health to establish a new Cancer Immunotherapy Trials Network to run clinical trials of the most promising new cancer immunotherapy treatments in development. TapImmune intends to continue enhancing its corporate leadership as well as seeking further beneficial partnerships.

Read More

Topics: ACT Biotech, breast cancer, Newsworthy Events

CEL-SCI’s progress toward the start of its Phase III trial

Posted by Laura Swartz

October 13, 2010 at 10:48 AM

CEL-SCI Corporation (CVM-NYSE Amex) is advancing its Phase III clinical trial of Multikine®, CEL-SCI’s lead immunotherapy product. Multikine® is being developed as a first-line standard-of-care treatment for head and neck cancer. In previous Phase II trials, this therapy was safe and well-tolerated, and had increased patient survival by 33% at a median of 3.5 years after treatment. Multikine® was also credited with eliminating head and neck cancer tumors in 12% of patients less than a month into treatment. On average, CEL-SCI’s new cancer therapy kills about 50% of tumor cells before patients have surgery or begin chemotherapy, which improves the likelihood of success of these standard treatments.

Read More

Topics: Newsworthy Events, CEL-SCI, Multikine

News from Generex, Pluristem, and Vena

Posted by Laura Swartz

October 12, 2010 at 10:50 AM

Read More

Topics: Cameco Corp, Newsworthy Events, Pluristem Therapeutics

Your unbiased source for under-the-radar investing ideas.

Posted by Laura Swartz

October 6, 2010 at 10:51 AM

Welcome to our blog.

Read More

Topics: Crystal Research Associates

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic